top
Search terms
Results 1 - 3 of 3 - ordered by :
Ehjournal

Abstract Aims Pexelizumab, a monoclonal antibody inhibiting C5, reduced 90 day mortality and shock in the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial without ...

European Heart Journal, Théroux, Pierre, Armstrong, Paul W., Mahaffey, Kenneth W., Hochman, Judith S., Malloy, Kevin J., Rollins, Scott, Nicolau, Jose C., Lavoie, Joel, Luong, The Minh, Burchenal, ...

Date : 01/10/2005
Ehjournal

Abstract Aims Pexelizumab, a monoclonal antibody inhibiting C5, reduced 90 day mortality and shock in the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial without ...

European Heart Journal, Théroux, Pierre, Armstrong, Paul W., Mahaffey, Kenneth W., Hochman, Judith S., Malloy, Kevin J., Rollins, Scott, Nicolau, Jose C., Lavoie, Joel, Luong, The Minh, Burchenal, ...

Date : 01/10/2005 Item size : 173396 bytes
Ehjournal

Abstract Aims Pexelizumab, a monoclonal antibody inhibiting C5, reduced 90 day mortality and shock in the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial without ...

European Heart Journal, Théroux, Pierre, Armstrong, Paul W., Mahaffey, Kenneth W., Hochman, Judith S., Malloy, Kevin J., Rollins, Scott, Nicolau, Jose C., Lavoie, Joel, Luong, The Minh, Burchenal, ...

Date : 01/10/2005